Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: A potential mechanism for efficacy in attention deficit/hyperactivity disorder

Neuropsychopharmacology

Volumn 27, Issue 5, 2002, Pages 699-711

  Bymaster, Frank P ^a   Katner, Jason S ^a   Nelson, David L ^a   Hemrick Luecke, Susan K ^a   Threlkeld, Penny G ^a   Heiligenstein, John H ^a   Morin, S Michelle ^a   Gehlert, Donald R ^a   Perry, Kenneth W ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Atomoxetine; Attention Deficit Hyperactivity Disorder; Dopamine; Fos expression; Methylphenidate; Microdialysis; Norepinephrine; Reboxetine

Indexed keywords

AMFEBUTAMONE; ATOMOXETINE; BIOCHEMICAL MARKER; DESIPRAMINE; DOPAMINE TRANSPORTER; FLUOXETINE; IMIPRAMINE; METHYLPHENIDATE; MONOAMINE; NOMIFENSINE; NORADRENALIN TRANSPORTER; NORADRENALIN UPTAKE INHIBITOR; PROTEIN FOS; PSYCHOSTIMULANT AGENT; RADIOLIGAND; REBOXETINE; SEROTONIN TRANSPORTER;

ANIMAL EXPERIMENT; ARTICLE; ATTENTION DEFICIT DISORDER; BRAIN NERVE CELL; BRAIN REGION; CLONE; CONTROLLED STUDY; CORPUS STRIATUM; DISSOCIATION CONSTANT; DRUG EFFICACY; DRUG MECHANISM; DRUG SELECTIVITY; GENETIC TRANSFECTION; LIGAND BINDING; MALE; MONOAMINE RELEASE; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; DOPAMINE; DRUG SYNERGISM; HUMANS; MALE; NOREPINEPHRINE; PREFRONTAL CORTEX; PROPYLAMINES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0036848458     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(02)00346-9     Document Type: Article

References (88)

1. American Psychiatric Association Diagnostic and Statistical manual of Mental Disorders. 4th ed:2000;American Psychiatric Association, Washington, DC.
2. Arnsten A.F. Catecholamine modulation of prefrontal cortical cognitive function. Trends Cogn Sci. 2:1998;436-447.
3. Arnsten A.F., Steere J.C., Hunt R.D. The contribution of alpha-2 noradrenergic mechanisms of prefrontal cortical cognitive function. potential significance for attention deficit hyperactivity disorder Arch Gen Psychiatry. 53:1996;448-455.
4. Aston-Jones G., Chiang C., Alexinsky T. Discharge of noradrenergic locus coeruleus neurons in behaving rats and monkeys suggests a role in vigilance. Prog Brain Res. 88:1991;501-520.
5. Barkley R.A. A review of stimulant drug research with hyperactive children. J Child Psychol Psychiatry. 18:1977;137-165.
6. Barkley R.A., Fischer M., Edelbrock C.S., Smallish L. The adolescent outcome of hyperactive children diagnosed by research criteria. I. An. 8-year(prospective follow-up study. J Am Acad Adolesc Psychiatry 29):1990;546-557.
7. Benson D.F., Stuss D.T. Motor abilities after frontal leukotomy. Neurol. 32:1982;1353-1357.
8. Berridge C.W., Arnsten A.F., Foote S.L. Noradrenergic modulation of cognitive function. clinical implications of anatomical, electrophysiological and behavioural studies in animal models Psychol Med. 23:1993;557-564.
9. Biederman J., Baldessarini R.J., Wright V., Knee D., Harmatz J.S. A double-blind placebo controlled study of desipramine in the treatment of ADD I. Efficacy. J Am Acad Child Adolesc Psychiatry. 28:1989;777-784.
10. Biederman J., Newcorn J., Sprich S. Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders. Am J Psychiatry. 148:1991;564-577.
11. Biederman J., Spencer T. Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder. Biol Psychiatry. 46:1999;1234-1242.
12. Bolden-Watson C., Richelson E. Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci. 52:1993;1023-1029.
13. Carboni E., Tanda G.L., Frau R., Di Chiara G. Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex. evidence that dopamine is taken up in vivo by noradrenergic terminals J Neurochem. 55:1990;1067-1070.
14. Castellanos F.X., Elia J., Kruesi M.J., Marsh W.L., Gulotta C.S., Potter W.Z., Ritchie G.F., Hamburger S.D., Rapoport J.L. Cerebrospinal fluid homovanillic acid predicts behavioral response to stimulants in 45 boys with attention deficit/hyperactivity disorder. Neuropsychopharmacol. 14:1996;125-137. a.
15. Castellanos F.X., Giedd J.N., Marsh W.L., Hamburger S.D., Vaituzis A.C., Dickstein D.P., Sarfatti S.E., Vauss Y.C., Snell J.W., Lange N., Kaysen D., Krain A.L., Ritchie G.F., Rajapakse J.C., Rapoport J.L. Quantitative brain magnetic resonance imaging in attention-deficit hyperactivity disorder. Arch Gen Psychiatry. 53:1996;607-616. b.
16. 50) of an enzymatic reaction. Biochem Pharmacol. 22:1973;3099-3108.
17. Chouinard G., Annable L., Bardwejn J. An early phase II clinical trial of tomoxetine (LY139603) in the treatment of newly admitted depressed patients. Psychopharmacol. 83:1984;126-128.
18. Cookson J. Side effects of antidepressants. Br J Psychiatry. 163(suppl 20):1993;20-24.
19. Coulter C.L., Happe H.K., Bergman D.A., Murrin L.C. Localization and quantification of the dopamine transporter. comparison of [3H]WIN 35,428 and [125I]RTI-55 Brain Res. 690:1995;217-224.
20. Delgado P.L., Miller H.L., Salomon R.M., Licinio J., Heninger G.R., Gelenberg A.J., Charney D.S. Monoamines and the mechanism of antidepressant action. effects of catecholamine depletion on mood of patients treated with antidepressants Psychopharmacol Bull. 29:1993;389-396.
21. Dennis T., L'Heureux R., Carter C., Scatton B. Presynaptic alpha-2 adrenoceptors play a major role in the effects of idazoxan on cortical noradrenaline release (as measured by in vivo dialysis) in the rat. J Pharmacol Exp Ther. 241:1987;642-649.
22. Devoto P., Flore G., Gessa G.L. Evidence for co-release of noradrenaline and dopamine from noradrenergic neurons in the cerebral cortex. Mol Psychiatry. 6:2001;657-664.
23. Di Chiara G., Tanda G.L., Frau R., Carboni E. Heterologous monoamine reuptake. lack of transmitter specificity of neuron-specific carriers Neurochem Int. 20:1992;231S-235S.
24. Dougherty D.D., Bonab A.A., Spencer T.J., Rauch S.L., Madras B.K., Fischman A.J. Dopamine transport density in patients with attention deficit hyperactivity disorder. Lancet. 354:1999;2132-2133.
25. Downey K.K., Stelson F.W., Pomerleau O.F., Giordani B. Adult attention deficit hyperactivity disorder. psychological test profiles in a clinical population J Nerv Ment Dis. 185:1997;32-38.
26. Dragunow M., Faull R. The use of c-fos as a metabolic marker in neuronal pathway tracing. J Neurosci Methods. 29:1989;261-265.
27. 99mTc]TRODAT-1 to the dopamine transporter before and after methylphenidate treatment Eur J Nucl Med. 27:2000;1518-1524.
28. During M.J., Bean A.J., Roth R.H. Effect of CNS stimulants on the in vivo release of the colocalized transmitters, dopamine and neurotensin, from rat prefrontal cortex. Neurosci Lett. 140:1992;129-133.
29. Elia J., Borcherding B.G., Rapoport J.L., Keysor C.S. Methylphenidate and dextroamphetamine treatments of hyperactivity. Are there true responders? Psychiatry Res. 36:1991;141-155.
30. Fuller R.W., Perry K.W. Lowering of epinephrine concentration in rat brain by 2,3-dichloro-alpha-methylbenzylamine, an inhibitor of norepinephrine N-methyltransferase. Biochem Pharmacol. 26:1977;2087-2090.
31. Fuller R.W., Perry K.W. Effects of buspirone and its metabolite, 1-(2-pyrimidinyl)piperazine, on brain monoamines and their metabolites in rats. J Pharmacol Exp Ther. 248:1989;50-56.
32. Gatley S.J., Pan D., Chen R., Chaturvedi G., Ding Y.-S. Affinities of methylphenidate derivatives for dopamine, norepinephrine and serotonin transporters. Life Sci. 58:1996;231-239.
33. 3H]-tomoxetine, an enantiomerically pure ligand for norepinephrine reuptake sites. Neurosci Lett. 157:1993;203-206.
34. Gehlert D.R., Schober D.A., Hemrick-Luecke S.K., Krushinski J., Howbert J.J., Robertson D.W., Fuller R.W., Wong D.T. Novel halogenated analogs of tomoxetine that are potent and selective inhibitors of norepinephrine uptake in brain. Neurochem Int. 26:1995;47-52.
35. Gittelman R. Childhood disorders. Klein D., Quitkin F., Rifkin A., Gittleman R. Drug Treatment of Adult and Childhood Disorders. 1980;576-756 Williams and Wilkins, Baltimore.
36. Gittelman R., Mannuzza S., Shenker R., Bonagura N. Hyperactive boys almost grown up. I. Psychiatric status. Arch Gen Psychiatry. 42:1985;937-947.
37. Greenhill L. Attention-deficit/hyperactivity disorder. the stimulants Child Adolesc Psychiatric Clin North Am. 4(1):1995;123-168.
38. Grenhoff J., Svensson T.H. Prazosin modulates the firing pattern of dopamine neurons in rat ventral tegmental area. Eur J Pharmacol. 233:1993;79-84.
39. Grzanna R., Berger U., Fritschy J.M., Geffard M. Acute action of DSP-4 on central norepinephrine axons. biochemical and immunohistochemical evidence for differential effects J Histochem Cytochem. 37:1989;1435-1442.
40. Holman R.B. Biological effects of central nervous system stimulants. Addiction. 89:1994;1435-1441.
41. Hynd G.W., Semrud-Clikeman M., Lorys A.R., Novey E.S., Eliopulos D. Brain morphology in developmental dyslexia and attention deficit disorder/hyperactivity. Arch Neurol. 47:1990;919-926.
42. Jonsson G., Hallman H., Ponzio F., Ross S. DSP4 (N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine)-a useful denervation tool for central and peripheral noradrenaline neurons. Eur J Pharmacol. 72:1981;173-188.
43. Krause K.-H., Dresel S.H., Krause J., Kung H.F., Tatsch K. Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder. effects of methylphenidate as measured by single photon emission computed tomography Neurosci Lett. 285:2000;107-110.
44. Kuczenski R., Segal D.S. Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine. comparison with amphetamine J Neurochem. 68:1997;2032-2037.
45. Kuczenski R., Segal D.S. Dynamic changes in sensitivity occur during the acute response to cocaine and methylphenidate. Psychopharmacol. 147:1999;96-103.
46. Leonard H.L., Meyer M.C., Swedo S.E., Richter D., Hamburger S.D., Allen A.J., Rapoport J.L., Tucker E. Electrocardiographic changes during desipramine and clomipramine treatment in children and adolescents. J Am Acad Child Adolesc Psychiatry. 34:1995;1460-1468.
47. Li X.M., Perry K.W., Wong D.T., Bymaster F.P. Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum. Psychopharmacol. 136:1998;153-161.
48. Lin J.S., Hou Y., Jouvet M. Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat. Proc Natl Acad Sci USA. 93:1996;14128-14133.
49. Linnèr L., Endersz H., Öhman D., Bengtsson F., Schalling M., Svensson T. Reboxetine modulates the firing pattern of dopamine cells in the ventral tegmental area and selectively increases dopamine availability in the prefrontal cortex. J Pharmacol Exp Ther. 297:2001;540-546.
50. Mannuzza S., Klein R.G., Bessler A., Malloy P., LaPadula M. Adult outcome of hyperactive boys. Educational achievement, occupational rank, and psychiatric status. Arch Gen Psychiatry. 50:1993;565-576.
51. Michelson D., Faries D., Wernicke J., Kelsey D., Kendrick K., Sallee F.R., Spencer T. Atomoxetine in the treatment of children and adolescents with Attention-Deficit/Hyperactivity Disorder. a randomized, placebo-controlled, dose-response study Pediatrics. 108:2001;e83.
52. Morgan J.I., Curran T. Inducible proto-oncogenes of the nervous system. their contribution to transcription factors and neuroplasticity Prog Brain Res. 86:1990;287-294.
53. Offord D.R., Boyle M.H., Szatmari P., Rae-Grant N.I., Links P.S., Cadman D.T., Byles J.A., Crawford J.W., Blum H.M., Byrne C. Ontario child health study. II. Six month prevalence of disorder and rates of service utilization. Arch Gen Psychiatry. 44:1987;832-836.
54. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 2nd ed:1986;Academic Press, San Diego.
55. Petrides M., Milner B. Deficits on subject-ordered tasks after frontal- and temporal-lobe lesions in man. Neuropsychologia. 20:1982;249-262.
56. Pliszka S.R., McCracken J.T., Maas J.W. Catecholamines in attention-deficit hyperactivity disorder. current perspectives J Am Acad Child Adolesc Psychiatry. 35:1996;264-272.
57. Raiteri M., Del Carmine R., Bertollini A., Levi G. Effect of sympathomimetic amines on the synaptosomal transport of noradrenaline, dopamine and 5-hydroxytryptamine. Eur J Pharmacol. 41:1977;133-143.
58. Robertson G.S., Matsumara H., Fibiger H.C. Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharmacol Exp Ther. 271:1994;1058-1066.
59. Sacchetti G., Bernini M., Bianchetti A., Parini S., Invernizzi R.W., Saminin R. Studies on the acute and chronic effects of reboxetine on extracellular noradrenaline and other monoamines in the rat brain. Br J Pharmacol. 128:1999;1332-1338.
60. Sawaguchi T., Goldman-Rakic P.S. The role of D1-dopamine receptor in working memory. Local injections of dopamine antagonists into the prefrontal cortex of Rhesus monkeys performing an oculomotor delayed-response task J Neurophysiol. 71:1994;515-528.
61. Sesack S.R., Hawrylak V.A., Matus C., Guido M.A., Levey A.I. Dopamine axon varicosities in the prelimbic division of the rat prefrontal cortex exhibit sparse immunoreactivity for the dopamine transporter. J Neurosci. 18:1998;2697-2708.
62. Segal M., Bloom F.E. The action of norepinephrine in the rat hippocampus. IV. The effects of locus coeruleus stimulation on evoked hippocampal unit activity. Brain Res. 107:1976;513-525.
63. Shi W.X., Pun C.L., Zhang X.X., Jones M.D., Bunney B.S. Dual effects of D-amphetamine on dopamine neurons mediated by dopamine and nondopamine receptors. J Neurosci. 20:2000;3504-3511.
64. Soucy J.P., Mrini A., Lafaille F., Doucet G., Descarries L. Comparative evaluation of [3H]WIN 35428 and [3H]GBR 12935 as markers of dopamine innervation density in brain. Synapse. 25:1997;163-175.
65. Spencer T., Biederman J., Heiligenstein J., Wilens T., Faries D., Prince J., Faraone S.V., Rea J., Witcher J., Zervas S. An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol. 11:2001;251-265.
66. Spencer T., Biederman J., Wilens T., Prince J., Hatch M., Jones J., Harding M., Faraone S.V., Seidman L. Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry. 155:1998;693-695.
67. Spencer T., Biederman J., Wilens T., Harding M., O'Donnell D., Griffin S. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry. 35:1996;409-432.
68. Spencer T., Wilens T., Biederman J., Faraone S.V., Ablon S., Lapey K. A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention deficit hyperactivity disorder. Arch Gen Psychiatry. 52:1995;434-443.
69. Szatmari P. The epidemiology of attention-deficit hyperactivity disorder. Child Adolesc Psychiatry Clin North Am. 1:1992;361-371.
70. Taber M.T., Das S., Fibiger H.C. Cortical regulation of subcortical dopamine release. mediation via the ventral tegmental area J Neurochem. 65:1995;1407-1410.
71. Taber M.T., Fibiger H.C. Electrical stimulation of the medial prefrontal cortex increases dopamine release in the striatum. Neuropsychopharmacol. 9:1993;271-275.
72. Tanda G., Carboni E., Frau R., Di Chiara G. Increase of extracellular dopamine in the prefrontal cortex. a trait of drugs with antidepressant potential? Psychopharmacol. 115:1994;285-288.
73. Tanda G., Pontieri F.E., Frau R., Di Chiara G. Contribution of blockade of the noradrenaline carrier to the increase of extracellular dopamine in the rat prefrontal cortex by amphetamine and cocaine. Eur J Neurosci. 9:1997;2077-2085.
74. Tatsumi M., Groshan K., Blakely R.D., Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 340:1997;249-258.
75. Thomas D.N., Holman R.B. A microdialysis study of the regulation of endogenous noradrenaline release in the rat hippocampus. J Neurochem. 56:1991;1741-1746.
76. Tidey J.W., Bergman J. Drug discrimination in methamphetamine-trained monkeys. agonist and antagonist effects of dopaminergic drugs J Pharmacol Exp Ther. 285:1998;1163-1174.
77. Volkow N.D., Wang G., Fowler J.S., Logan J., Gerasimov M., Maynard L., Ding Y.-S., Gatley S.J., Gifford A., Franceschi D. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci. 21,(RC121):2001;1-5.
78. Walsh B.T., Giardina E.G., Sloan R.P., Greenhill L., Goldfein J. Effects of desipramine on autonomic control of the heart. J Am Acad Child Adolesc Psychiatry. 33:1994;191-197.
79. Wilens T.E., Biederman J., Prince J., Spencer T.J., Faraone S.V., Warburton R., Schleifer D., Harding M., Linehan C., Geller D. Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder. Am J Psychiatry. 153:1996;1147-1153.
80. Wilens T.E., Biederman J., Spencer T.J. Pharmacotherapy of attention deficit hyperactivity disorder in adults. CNS Drugs. 9:1998;347-356.
81. Wilens T.E., Spencer T.J. The stimulants revisited. Child Adolesc Clin North Am. 9:2000;573-603.
82. Wong D.T., Threlkeld P.G., Best K.L., Bymaster F.P. A new inhibitor of norepinephrine uptake devoid of affinity for receptors in rat brain. J Pharmacol Exp Ther. 222:1982;61-65.
83. Wong D.T., Bymaster F.P., Engleman E.E. Prozac (fluoxetine, Lilly 110140), the first selective uptake inhibitor and an antidepressant drug. twenty years since its first publication Life Sci. 57:1995;411-441.
84. Wong D.T., Horng J.S., Bymaster F.P. dl-N-Methyl-3-(o-methoxyphenoxy)-3-phenylpropylamine hydrochloride, Lilly 94939, a potent inhibitor for uptake of norepinephrine into rat brain synaptosomes and heart. Life Sci. 17:1975;755-760.
85. Wong E.H.F., Sonders M.S., Amara S.G., Tinholt P.M., Piercey M.F.P., Hoffman W.P., Hyslop D.K., Franklin S., Porsolt R.D., Bonsignori A., Carfagna N., McArthur R.A. Reboxetine. A pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor Biol Psychiatry. 47:2000;818-829.
86. Yamamoto B.K., Novotney S. Regulation of extracellular dopamine by the norepinephrine transporter. J Neurochem. 71:1998;274-280.
87. Zametkin A.J., Rapoport J.L. Noradrenergic hypothesis of attention deficit disorder with hyperactivity. a critical review Meltzer H.Y. Psychopharmacology. the Third Generation of Progress:1987;837-847 Raven Press, New York.
88. Zhang W., Perry K.W., Wong D.T., Potts B., Tollefson G.D., By-master F.P. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology. 23:2000;250-262.